Novartis: Sandoz applies for blood cancer drug biosimilar.
(CercleFinance.com) - Sandoz said on Tuesday that it has applied to the US FDA for approval to sell its version of Biogen's Rituxan, a treatment for blood cancers.
The Novartis unit said that the Food and Drug Administration has accepted its biologics license application (BLA).
Rituxan is used to treat blood cancers including non-Hodgkin's lymphoma and chronic lymphocytic leukemia, as well as immunological diseases such as rheumatoid arthritis.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The Novartis unit said that the Food and Drug Administration has accepted its biologics license application (BLA).
Rituxan is used to treat blood cancers including non-Hodgkin's lymphoma and chronic lymphocytic leukemia, as well as immunological diseases such as rheumatoid arthritis.
Copyright (c) 2017 CercleFinance.com. All rights reserved.